Genetic testing company 23andMe has filed for Chapter 11 bankruptcy protection, leading to concerns over the potential sale of the DNA data of millions of users. Privacy advocates and experts worry about the consequences of this sale, as users have no control over where their data may end up. California Attorney General Rob Bonta has warned users that their data could be sold, offering instructions on how to delete genetic data and revoke access to third-party research studies.
The sensitivity of DNA data, which can reveal predisposed genetic conditions and be used in criminal investigations, raises concerns about potential misuse by bad actors. While 23andMe claims there will be no changes in how they store data, experts point out that genetic data held by tech companies like 23andMe is not as regulated as data held by medical professionals under HIPAA.
There is precedent for breaches of user data at 23andMe, with a hacker gaining access to the data of millions of users in 2023. This highlights the risks associated with sharing genetic information with corporations. Georgetown Law’s Emily Tucker emphasizes the need for individuals to understand the risks involved in sharing their DNA with companies and the potential consequences for their genetic privacy and that of their relatives.
The sale of 23andMe serves as a wake-up call for Americans to be more cautious about sharing their personal information without adequate safeguards in place. The lack of federal regulation for genetic data held by tech companies underscores the need for stronger privacy laws to protect individuals’ sensitive information.
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
